Skip to main content
PMC home page
Gut logoLink to Gut
. 1997 Jul;41(1):8–13. doi: 10.1136/gut.41.1.8

Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. European Helicobacter Pylori Study Group.

PMCID: PMC1027220  PMID: 9274464

Abstract

There is considerable confusion over the management of Helicobacter pylori infection, particularly among primary care physicians, and numerous European countries lack national guidelines in this rapidly growing area of medicine. The European Helicobacter Pylori Study Group therefore organised a meeting in Maastricht of H pylori experts, primary care physicians and representatives of National Societies of Gastroenterology from Europe to establish consensus guidelines on the management of H pylori at the primary care and specialist levels, and to consider general health care issues associated with the infection. As in previous guidelines, eradication therapy was recommended in all H pylori positive patients with peptic ulcer disease. Additionally, at the primary care level in dyspeptic patients < 45 years old and with no alarm symptoms, diagnosis is recommended by non-invasive means (13C urea breath test, serology) and if H pylori positive the patient should be treated. Moreover, at the specialist level the indications for eradication of H pylori were also broadened to include H pylori positive patients with functional dyspepsia in whom no other possible causes of symptoms are identified by the specialist (after a full investigation including endoscopy, ultrasound and other necessary investigations), patients with low grade gastric mucosa associated lymphoid tissue (MALT) lymphoma (managed in specialised centres) and those with gastritis with severe macro- or microscopic abnormalities. There was consensus that treatment regimens should be simple, well tolerated and achieve an eradication rate of over 80% on an intention to treat basis. It was strongly recommended, therefore, that eradication treatment should be with proton pump inhibitor based triple therapy for seven days, using a proton pump inhibitor and two of the following: clarithromycin, a nitroimidazole (metronidazole or tinidazole) and amoxycillin.

Full text

PDF
8

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bell G. D., Powell K. U., Burridge S. M., Bowden A. F., Atoyebi W., Bolton G. H., Jones P. H., Brown C. Rapid eradication of Helicobacter pylori infection. Aliment Pharmacol Ther. 1995 Feb;9(1):41–46. doi: 10.1111/j.1365-2036.1995.tb00349.x. [DOI] [PubMed] [Google Scholar]
  2. Bell G. D., Powell K. U., Burridge S. M., Bowden A. F., Atoyebi W., Bolton G. H., Jones P. H., Brown C. Rapid eradication of Helicobacter pylori infection. Aliment Pharmacol Ther. 1995 Feb;9(1):41–46. doi: 10.1111/j.1365-2036.1995.tb00349.x. [DOI] [PubMed] [Google Scholar]
  3. Briggs A. H., Sculpher M. J., Logan R. P., Aldous J., Ramsay M. E., Baron J. H. Cost effectiveness of screening for and eradication of Helicobacter pylori in management of dyspeptic patients under 45 years of age. BMJ. 1996 May 25;312(7042):1321–1325. doi: 10.1136/bmj.312.7042.1321. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Buckley M., O'Morain C. Helicobacter pylori eradication--a surrogate marker for duodenal ulcer healing. Eur J Gastroenterol Hepatol. 1996 May;8(5):415–416. [PubMed] [Google Scholar]
  5. Digestive Disease Week and the 96th annual meeting of the American Gastroenterological Association. San Francisco, California, May 19-22, 1996. Abstracts. Gastroenterology. 1996 Apr;110(4 Suppl):A1–1591. [PubMed] [Google Scholar]
  6. Digestive Disease Week and the 96th annual meeting of the American Gastroenterological Association. San Francisco, California, May 19-22, 1996. Abstracts. Gastroenterology. 1996 Apr;110(4 Suppl):A1–1591. [PubMed] [Google Scholar]
  7. Dixon M. F., Genta R. M., Yardley J. H., Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol. 1996 Oct;20(10):1161–1181. doi: 10.1097/00000478-199610000-00001. [DOI] [PubMed] [Google Scholar]
  8. Feldman R. A., Deeks J. J., Evans S. J. Multi-laboratory comparison of eight commercially available Helicobacter pylori serology kits. Helicobacter pylori Serology Study Group. Eur J Clin Microbiol Infect Dis. 1995 May;14(5):428–433. doi: 10.1007/BF02114899. [DOI] [PubMed] [Google Scholar]
  9. Fendrick A. M., Chernew M. E., Hirth R. A., Bloom B. S. Alternative management strategies for patients with suspected peptic ulcer disease. Ann Intern Med. 1995 Aug 15;123(4):260–268. doi: 10.7326/0003-4819-123-4-199508150-00003. [DOI] [PubMed] [Google Scholar]
  10. Graham D. Y., Hepps K. S., Ramirez F. C., Lew G. M., Saeed Z. A. Treatment of Helicobacter pylori reduces the rate of rebleeding in peptic ulcer disease. Scand J Gastroenterol. 1993 Nov;28(11):939–942. doi: 10.3109/00365529309098288. [DOI] [PubMed] [Google Scholar]
  11. Heikkinen M., Pikkarainen P., Takala J., Räsänen H., Julkunen R. Etiology of dyspepsia: four hundred unselected consecutive patients in general practice. Scand J Gastroenterol. 1995 Jun;30(6):519–523. doi: 10.3109/00365529509089783. [DOI] [PubMed] [Google Scholar]
  12. Hopkins R. J., Girardi L. S., Turney E. A. Relationship between Helicobacter pylori eradication and reduced duodenal and gastric ulcer recurrence: a review. Gastroenterology. 1996 Apr;110(4):1244–1252. doi: 10.1053/gast.1996.v110.pm8613015. [DOI] [PubMed] [Google Scholar]
  13. Jaup B. H., Norrby A. Low dose, short-term triple therapy for cure of Helicobacter pylori infection and healing of peptic ulcers. Am J Gastroenterol. 1995 Jun;90(6):943–945. [PubMed] [Google Scholar]
  14. Kosunen T. U., Seppälä K., Sarna S., Sipponen P. Diagnostic value of decreasing IgG, IgA, and IgM antibody titres after eradication of Helicobacter pylori. Lancet. 1992 Apr 11;339(8798):893–895. doi: 10.1016/0140-6736(92)90929-w. [DOI] [PubMed] [Google Scholar]
  15. Kuipers E. J., Lundell L., Klinkenberg-Knol E. C., Havu N., Festen H. P., Liedman B., Lamers C. B., Jansen J. B., Dalenback J., Snel P. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med. 1996 Apr 18;334(16):1018–1022. doi: 10.1056/NEJM199604183341603. [DOI] [PubMed] [Google Scholar]
  16. Labenz J., Börsch G. Role of Helicobacter pylori eradication in the prevention of peptic ulcer bleeding relapse. Digestion. 1994;55(1):19–23. doi: 10.1159/000201117. [DOI] [PubMed] [Google Scholar]
  17. Labenz J., Peitz U., Tillenburg B., Becker T., Börsch G., Stolte M. Kurzzeit-Tripel-Therapie mit Pantoprazol, Clarithromycin und Metronidazol zur Eradikation von Helicobacter pylori. Leber Magen Darm. 1995 May;25(3):122, 125-7. [PubMed] [Google Scholar]
  18. Labenz J., Stolte M., Rühl G. H., Becker T., Tillenburg B., Sollböhmer M., Börsch G. One-week low-dose triple therapy for the eradication of Helicobacter pylori infection. Eur J Gastroenterol Hepatol. 1995 Jan;7(1):9–11. [PubMed] [Google Scholar]
  19. Labenz J., Tillenburg B., Peitz U., Börsch G. Long-term consequences of Helicobacter pylori eradication: clinical aspects. Scand J Gastroenterol Suppl. 1996;215:111–115. [PubMed] [Google Scholar]
  20. Lind T., Veldhuyzen van Zanten S., Unge P., Spiller R., Bayerdörffer E., O'Morain C., Bardhan K. D., Bradette M., Chiba N., Wrangstadh M. Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH I Study. Helicobacter. 1996 Sep;1(3):138–144. doi: 10.1111/j.1523-5378.1996.tb00027.x. [DOI] [PubMed] [Google Scholar]
  21. Lind T., Veldhuyzen van Zanten S., Unge P., Spiller R., Bayerdörffer E., O'Morain C., Bardhan K. D., Bradette M., Chiba N., Wrangstadh M. Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH I Study. Helicobacter. 1996 Sep;1(3):138–144. doi: 10.1111/j.1523-5378.1996.tb00027.x. [DOI] [PubMed] [Google Scholar]
  22. McCarthy C., Patchett S., Collins R. M., Beattie S., Keane C., O'Morain C. Long-term prospective study of Helicobacter pylori in nonulcer dyspepsia. Dig Dis Sci. 1995 Jan;40(1):114–119. doi: 10.1007/BF02063953. [DOI] [PubMed] [Google Scholar]
  23. Miehlke S., Bayerdörffer E., Lehn N., Mannes G. A., Höchter W., Weingart J., Sommer A., Heldwein W., Müller-Lissner S., Bästlein E. Recurrence of duodenal ulcers during five years of follow-up after cure of Helicobacter pylori infection. Eur J Gastroenterol Hepatol. 1995 Oct;7(10):975–978. doi: 10.1097/00042737-199510000-00012. [DOI] [PubMed] [Google Scholar]
  24. Moayyedi P., Sahay P., Tompkins D. S., Axon A. T. Efficacy and optimum dose of omeprazole in a new 1-week triple therapy regimen to eradicate Helicobacter pylori. Eur J Gastroenterol Hepatol. 1995 Sep;7(9):835–840. [PubMed] [Google Scholar]
  26. Patel P., Khulusi S., Mendall M. A., Lloyd R., Jazrawi R., Maxwell J. D., Northfield T. C. Prospective screening of dyspeptic patients by Helicobacter pylori serology. Lancet. 1995 Nov 18;346(8986):1315–1318. doi: 10.1016/s0140-6736(95)92340-3. [DOI] [PubMed] [Google Scholar]
  27. Penston J. G., Mistry K. R. Eradication of Helicobacter pylori in general practice. Aliment Pharmacol Ther. 1996 Apr;10(2):139–145. doi: 10.1046/j.1365-2036.1996.745128000.x. [DOI] [PubMed] [Google Scholar]
  28. Phull P. S., Ryder S. D., Halliday D., Price A. B., Levi A. J., Jacyna M. R. The economic and quality-of-life benefits of Helicobacter pylori eradication in chronic duodenal ulcer disease--a community-based study. Postgrad Med J. 1995 Jul;71(837):413–418. doi: 10.1136/pgmj.71.837.413. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Rokkas T., Karameris A., Mavrogeorgis A., Rallis E., Giannikos N. Eradication of Helicobacter pylori reduces the possibility of rebleeding in peptic ulcer disease. Gastrointest Endosc. 1995 Jan;41(1):1–4. doi: 10.1016/s0016-5107(95)70266-0. [DOI] [PubMed] [Google Scholar]
  30. Sobala G. M., Crabtree J. E., Pentith J. A., Rathbone B. J., Shallcross T. M., Wyatt J. I., Dixon M. F., Heatley R. V., Axon A. T. Screening dyspepsia by serology to Helicobacter pylori. Lancet. 1991 Jul 13;338(8759):94–96. doi: 10.1016/0140-6736(91)90085-4. [DOI] [PubMed] [Google Scholar]
  31. Sonnenberg A. Cost-benefit analysis of testing for Helicobacter pylori in dyspeptic subjects. Am J Gastroenterol. 1996 Sep;91(9):1773–1777. [PubMed] [Google Scholar]
  32. Talley N. J. A critique of therapeutic trials in Helicobacter pylori-positive functional dyspepsia. Gastroenterology. 1994 May;106(5):1174–1183. doi: 10.1016/0016-5085(94)90007-8. [DOI] [PubMed] [Google Scholar]
  33. Tham T. C., McLaughlin N., Hughes D. F., Ferguson M., Crosbie J. J., Madden M., Namnyak S., O'Connor F. A. Possible role of Helicobacter pylori serology in reducing endoscopy workload. Postgrad Med J. 1994 Nov;70(829):809–812. doi: 10.1136/pgmj.70.829.809. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Unge P. Review of Helicobacter pylori eradication regimens. Scand J Gastroenterol Suppl. 1996;215:74–81. [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES